Clinical Trial Update: Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating OM85 for reducing acute severe respiratory events in health care workers during the COVID-19 pandemic has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• OM85 (Omalmode (OM-85)))

Snippet

Sponsor: The University of Queensland | Conditions: Respiratory Viral Infection, Covid19 | Phase 3 | Status: COMPLETED